Hypertension has been labeled as a cause of non-diabetic chronic kidney disease for decades. In today's era of precision medicine, labeling benign hypertension as the initial etiology for chronic kidney disease might not be accurate. We discuss an example of a 55-year-old African American patient with pathologic findings of nephrosclerosis without history of hypertension. The pathologic findings of nephrosclerosis can be result of obesity, aging, genetic susceptibility and variety of other previously undiagnosed primary renal disease, and hence shouldn't be automatically mark hypertensive nephrosclerosis. Multiple studies to date have failed to prove or refute causality between benign hypertension and non-diabetic chronic kidney disease. Genome sequencing of non-diabetic kidney diseases have identified mutations in Apolipoprotein L1 gene, MYH9 gene, and uromodulin gene as risk factors for chronic kidney disease. There is no dispute that uncontrolled hypertension leads to progression of kidney disease and that blood pressure should be controlled adequately. The relationship between hypertension and kidney dysfunction should be viewed as an association and broad differential diagnoses should be pursued.
Case Discussion
A 55-year-old African American man presented to the hospital with intermittent nausea and fatigue. He was noted to have a creatinine peak of 7.1 mg/dl from his baseline of 2.6-3.2 mg/dL. He had a history chronic kidney disease of unknown etiology for 6 years with serum creatinine of 1.5 mg/dl 4 years prior to presentation. His blood pressure (BP) on presentation was 133/75 mmHg and remained controlled during the seven-day hospital stay with average blood pressure ranging from 113-125/ 60-75 mmHg with occasional systolic readings of 140-150 mmHg. He didn't have access to regular health care. His body mass index (BMI) was 27 kg/m 2 . He didn't have a history of hypertension, diabetes mellitus, coronary artery disease, nephrolithiasis, or pyelonephritis. He had a history of untreated hepatitis C with viral load of 1,115 copies/ml diagnosed a year prior to this presentation. A year prior to this admission, his blood pressure was 125/88 mmHg. There was documentation of one isolated systolic blood pressure of 140 mmHg a year prior. Even prior to the diagnosis of CKD 6 years ago, he didn't have history of high blood pressure. He was never on any antihypertensive medications in the past. His urine protein: creatinine ratio a year prior to the presentation was 460 mg/g. Home medications included calcium and magnesium supplements for cramps. He had history of chronic back pain. He had remote use of intermittent non-steroidal anti-inflammatory agents (NSAIDS). He was born at term and didn't have any complications at birth or major illnesses during childhood. He didn't have a family history of kidney disease or hypertension. He didn't have history of smoking, alcohol or recreational drugs. He didn't have history of blood transfusion. He worked as a driver and didn't have occupational exposure to toxic chemicals or heavy metals.
Upon further evaluation, on this admission his 24-hour urine protein was 6.7 g. A kidney ultrasound showed a right kidney measuring 10.7 cm and left kidney measuring 11 cm without hydronephrosis. Urine sediment showed few white cells, non-dysmorphic red cells and many waxy casts per high power field. Complement levels were low, with C3 49 mg/dL (79-152) and C4 13 mg/dL . Free light chains were normal. Uric acid level was 9.0 mg/dL ANA, rheumatoid factor, cryoglobulins were negative. Lactate dehydrogenase was 324 U/L (118-273) and
haptoglobin of 37 mg/dL (36-196mg/dL ).
In addition to worsening renal function, the proteinuria had worsened from 460mg/g a year prior to 6.7 g on admission. With the initial differential diagnosis of hepatitis C related kidney disease considering proteinuria, hypocomplementemia and history of untreated hepatitis C infection, a kidney biopsy was performed. The biopsy specimen consisted of three cores containing approximately 80% renal cortex and 20% medulla. The biopsy showed 9 glomeruli of which 55% were globally sclerosed. were identified. (Figure 1 and 2). These biopsy findings were reported to be consistent with vascular mediated glomerular injury (glomerular hypoperfusion) secondary to severe chronic renovascular sclerosis. Non-obsolescent glomerulus has prominent periglomerular fibrosis. Mesangial matrix is mildly and segmentally expanded with no significant increase in cellularity. There are no crescents, necrosis or thrombi identified.
Interestingly, the patient didn't have history of uncontrolled hypertension which was supported by his blood pressure trends in the hospital and limited blood pressure readings on ambulatory settings. Because ambulatory readings were not possible to obtain due to patient's lack of routine outpatient care, periodic masked hypertension outside of the hospital would be difficult to obtain. Hence, in addition to close monitoring of his blood pressure in the hospital, work up for secondary causes of hypertension for episodic masked hypertension were pursued. He only had mildly elevated plasma metanephrines at 66 pg/mL (reference <57) with normal normetanephrine level at 142 pg/ml (reference <148). 24-hour urine nor-metanephrine was 351 mcg (reference-122-676 mcg/24hr) and total epinephrine plus norepinephrine was 7 (26-121 mcg/24 h). These findings wouldn't support diagnosis of pheochromocytoma. His clinical presentation was also not suggestive of pheochromocytoma.
The diagnosis of hypertensive nephrosclerosis has been given to many patients with CKD based on the described pathologic findings. 
Discussion of Literature Review

The burden of hypertension
Hypertension has been known for many decades to be a major risk factor for myocardial infarction, heart failure, stroke, peripheral artery disease, atrial fibrillation and chronic kidney disease, and has been referred to as a "silent killer" [10] . The burden of hypertension in cardiovascular disease is well established. Hypertension treatment has been shown to decrease cardiovascular risk as demonstrated in the Veteran's Affairs Cooperative trials of the late 1960s to 1970s [11, 12] . However, hypertension is an aging disorder, and in the United States, among the estimated 85.7 million adults with hypertension (defined as blood pressure (BP) greater than or equal to 140/90 mm Hg) <10% of persons aged <40 years compared to two-thirds of persons aged ≥ 60 years have hypertension [10, 13] . According to United Stated Renal Data System (USRDS) annual report prevalence of CKD in patients with hypertension was
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reported as 31% [14] . Despite the widespread reporting of hypertension as a cause of CKD, the mechanism of nonmalignant hypertension as a risk factor of chronic kidney disease is a subject of an interesting debate.
Definition and history of hypertensive nephrosclerosis
Hypertensive nephrosclerosis has been defined in the literature as a non-diabetic chronic kidney disease associated with chronic hypertension, with or without proteinuria, and a pathologic picture characterized by arteriosclerosis, arteriolosclerosis, glomerulosclerosis, and interstitial fibrosis without immune deposits [1, 10] . The term nephrosclerosis was initially derived from the Greek word "nephros, kidney; sklerosis, hardening," resulting from dense collagenous tissue replacing normal kidney parenchyma attributed to hypertension [11] . The history of hypertensive nephrosclerosis first started in 1873 when Dr. Stewart described the pathologic findings in a fibrotic kidney which was previously described as "the morbid changes in the arteriole and capillaries in the primary and essential condition of the morbid state called chronic Bright's disease with contracting kidneys" [12] . However, it remains to date a topic of debate whether the non-malignant hypertension is indeed the culprit for this scarring in these kidneys labeled as hypertensive nephrosclerosis.
How is nephrosclerosis described?
Hypertension is described as a cause for renal vascular injury, including ischemia and hypertrophy of glomeruli, vessels, and tubules [1, 13] . Arteriosclerosis and arteriolosclerosis are characterized by muscular hyperplasia leading to narrowing of arteriolar lumen, intimal fibrosis, arteriolar hyalinosis that appears as focal lesions with homogenous eosinophilic acellular material that stains brightly on periodic acid-Schiff staining [1, 11] . The interlobar arteries have fibroelastic thickening and medial scarring [11] . Other pathologic findings are global glomerulosclerosis predominantly obsolescence characterized by collapse of the glomerular tuft and intracapsular fibrosis, segmental glomerulosclerosis, tubulointerstitial changes, tubular atrophy, inflammation and fibrosis [1, 14, 15] . These pathologic findings summarized as nephrosclerosis have been attributed in literature and in practice to preceding hypertension induced preglomerular microvascular injury, atherosclerotic narrowing of preglomerular arteries and arterioles leading to reduced glomerular perfusion [11, 16] .
Is hypertension a cause for CKD or mere association?
Since the 1800s, hypertension has remained the second most common etiology for ESKD [10] . Systolic hypertension has been reported as a powerful predictor of the development of ESKD [17, 18] . Hypertensive urgency as a cause for acute kidney injury with fibrinoid necrosis in the arterioles from the shear stress on the vascular wall is understandable, but the pathogenesis of hypertensive nephrosclerosis from essential hypertension still remains unclear [10] . MRFIT trial had shown a strong graded association of systolic and diastolic blood pressures with development of ESKD irrespective of other demographic variables, diabetes, myocardial infarction, smoking and dyslipidemia [17] . However, baseline kidney function was not assessed in the majority of this cohort making it 
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unclear if renal dysfunction was already present in patients who developed ESKD later [17] . In a subsequent study, Iseki et al. adjusted the baseline serum creatinine, proteinuria and hematuria to demonstrate that high blood pressure alone was, in fact, not a risk factor for ESKD [19] . In the African American Study of Kidney Disease (AASK) Study, kidney biopsies were performed in 39 patients, with mean blood pressures were 109 +/-15 and GFR 52+/-13 ml/min which showed findings of arteriosclerosis/arteriolosclerosis, glomerulosclerosis, basement membrane thickening, global glomerulosclerosis, tubular atrophy and interstitial fibrosis [13] . Based on these pathologic findings with correlation to their systolic blood pressures, the authors concluded that the non-diabetic hypertensive African American patient have renal vascular changes supportive of hypertensive nephrosclerosis [13] . However, these biopsies and blood pressure correlation were cross-sectional findings with no prior baseline renal function or the trends in blood pressures to show if the renal findings preceded or followed the rise in blood pressure. All the epidemiologic and observational studies demonstrate that hypertension and CKD are closely linked, but we cannot prove causality and make a statement that benign hypertension causes CKD.
The argument against causality linking hypertension to CKD is not new. In 1993, Perneger stated that progression to blockers for hypertension [7] . This study demonstrated that there is no difference in relative risk of developing kidney dysfunction among patients randomized to antihypertensive therapy with relative risk of 0.95 (95% confidence interval of 0.58-1.55, p value of 0.48) [7] . This meta-analysis was repeated including secondary analysis, and still didn't show reduction in incidence of kidney dysfunction in the treatment versus control group, with a relative risk of 0.97 (95% CI:0.78-1.21, p=0.77). (7) In another cohort of 2,125 mild to moderate hypertensive men, in-treatment diastolic pressure was not independently associated with final serum creatinine [21] . The development of kidney dysfunction in patients with non-malignant hypertension irrespective of treatment suggests that renal dysfunction is most likely a result of an intrinsic kidney disease. Even though treatment of mild HTN does not seem to affect renal outcomes unlike effect on cardiovascular outcomes, the treatment of hypertension with blockers of the renin angiotensin aldosterone blockade may have an impact on the kidney disease especially with proteinuria and hence should be treated.
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Hypertension is often implicated as the cause of most non-diabetic CKD that doesn't have other obvious etiology.
The pathogenesis for development of kidney injury has been poorly described for benign hypertension but is better explained when hypertension and CKD are considered as an association taking in to account genetic predisposition, racial differences in susceptibility to hypertension, and kidney damage [1, 4] . Several studies have suggested that reduced nephron number and nephron hypertrophy play a role in the development of hypertension and the progression of renal disease [1, [22] [23] [24] [25] . In an autopsy study by Hughson et al, hypertensive subjects had larger glomeruli compared to non-hypertensive subjects, independent of race or gender [16] . African American males had significantly larger glomeruli than white males [16] . As postulated by Hughson, the glomerular hypertrophy and hypertension could have developmental associations with glomerulosclerosis and arterial intimal thickening which appears to be more common in African American population. In the African American Study of Kidney Disease (AASK) Study, African Americans had more severe arteriosclerosis, glomerulosclerosis and more frequent solidification of glomeruli compared to Whites irrespective of difference in blood pressures due to race in the biopsy series of patients labeled as hypertensive nephrosclerosis [16, 26, 27] . These findings do not support or refute the causality between the findings of nephrosclerosis and hypertension but rather suggests an association.
A study of 94 patients treated for benign hypertension showed despite good control of diastolic blood pressure (less than or equal to 90 mm Hg), African American patients were twice as likely as Caucasian patients to have elevations in serum creatinine (23 percent vs. 11 percent) [28] . Lipkowitz also described that the progressive decline in renal function was unlikely caused by essential hypertension as the results of decline in renal function were consistent when comparing hypertensive AASK cases to controls with or without high BP and lower blood pressure goal didn't slow the progression of renal disease in African American population [29] . In numerous studies like these , ESKD attributed to hypertension has been more strongly associated in African Americans than white population [18] . This should bring to attention that there should be another risk factor independent from blood pressure that is causing renal dysfunction in African American population that predisposes them to both with CKD and hypertension.
Genetics behind the hypertension and CKD
Studies showing a racial predisposition and non-significant effect of treatment on the development of kidney disease suggest that there may be another independent risk factor for CKD and hypertension. Now, we have increasing data on this racial predisposition of presumed hypertension attributed CKD and ESKD, with the identification of the region on chromosome 22q that contains the genes-non-muscle myosin heavy chain type 2 (MYH9) and
apolipoprotein-L1 (APOL1) [29, 30] . The association of non-diabetic kidney disease including FSGS and hypertension in African American population with APOL1 variants has provided a greater understanding about this racial predisposition as well [16] .
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APOL1 gene variants are known to be associated with non-diabetic chronic kidney disease and ESKD in African Americans while MYH9 risk alleles with individuals of European ancestry [29] . The association has been reported at a higher rate for variants in APOL1 gene and African American ancestry than with white patients [31] . The APOL1
two-risk variants were present in 10% of patients with hypertension-attributed CKD, 6% of their first-degree relatives and 8.6% of controls [31] . These variants of APOL1 (termed G1 and G2) had evolved to protect from a species of trypanosomal infection in African population and now has been carried worldwide in descendants of the population from the geographic region [32] . G1 and/or G2 APOL1 risk variants were present in more than 30% of African American chromosomes [33] . Approximately 12% of HIV-negative and 50% of HIV-positive African American APOL1 G1/G2 homozygotes or compound heterozygotes may be susceptible to kidney disease [30] .
Apolipoproteins are structurally and functionally similar to proteins in the BCl2 family which play a role in apoptosis and hence the possibility that it has role in the apoptosis in the kidney resulting in glomerulosclerosis [30, 34] . The G1 and G2 APOL1 variants have dysunctional particle which is potential etiology for inflammation in the renal vascular endothelisum resulting in arteriolar nephrosclerosis as a pathogenesis of CKD [30] .
African American subjects with one APOL1 risk allele vs zero risk allele have odds ratio (OR) of 1.26 and with two risk alleles vs zero risk allenes have OR of 7.3 for ESKD labeled as hypertension associated with relation to susceptibility for glomerulosclerosis [16, 30, 33] . It has been postulated that APOL1 risk alleles may be associated with glomerular enlargement [35] . Glomerular number (Nglom) and mean glomerular volume (Vglom) were measured in kidneys of African-American and non-African-American adults without renal disease, undergoing autopsies in Jackson, Mississippi and their APOL1 risk alleles were genotyped [35] . The proportions of African
Americans with zero, one, and two APOL1 risk alleles were 38%, 43%, and 19%, respectively; 38% of African Americans had G1 allele variants and 31% of African Americans had G2 allele variants [35] . Only APOL1-positive African Americans had significant reductions in Nglom but with increase in volume with increasing age [35] . AASK cohort had findings of focal global glomerulosclerosis, arteriolar nephrosclerosis and interstitial scarring in the renal biopsies which is this disease-spectrum based on APOL1 association [13] . This would suggest that the pathologic findings in many of the patients labeled as hypertensive nephrosclerosis may have APOL1 risk variants. This has been demonstrated in the prospective clinical outcome study of ESKD by Foster in 2013 in which the presence of two risk alleles conferred a 1.49-fold increased risk of CKD (95% CI=1.02 to 2.17) and a 1.88-fold increased risk of ESKD (95% CI=1.20 to 2.93) compared with zero or one risk allele [36] . Many studies have conclusively confirmed the causal link beteween APOL1 gene variants and CKD [4, 30, 33, 36] . This also explains the racial differences in the susceptibility to renal damage from elevated blood pressures and increased risk for ESKD attributed to hypertension in African Americans.
In addition to APOL1 gene variants associated with CKD, recent data have confirmed other missed genetic diagnoses with exome sequencing of CKD cohorts [37] . We have enough evidence that requires reconsideration and 
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further exploration of other genetic risk factors and causes for development of CKD and progression to ESKD in patients with benign hypertension. Recently another entity known as serum uromodulin, has been described as independently associated with progression of CKD and ESKD [38] . Mutations in the uromodulin (UMOD) gene, which encodes uromodulin (Tamm-Horsfall protein) have been identified as a cause of hereditary autosomaldominant tubulointerstitial diseases [38] [39] [40] . The variants in UMOD gene have also been recognized as the risk factors for CKD and hypertension [38, [41] [42] [43] .
The relationship between hypertension and kidney dysfunction needs to be labeled as an association until causality is conclusively established. Nephrosclerosis on kidney biopsy is mostly driven by aging but also by obesity, and potentially genetic susceptibility. Hypertension is potentially a consequence or a simultaneous manifestation of an undiagnosed kidney parenchymal disease or renal vascular disease [11] . We know that blood pressure reduction in chronic kidney disease decreases risk of progression, regardless of the etiology of chronic kidney disease [44] .
Uncontrolled hypertension potentiates the injury to kidney parenchyma and vessels and should be adequately treated, but we would like to suggest that mild to moderate elevations in high blood pressure is likely not the initial insult for the kidney dysfunction.
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Conclusion
We have enough evidence to support that the genetic variants are associated with pathologic findings on kidney biosies that drive renal dysfunction as well as hypertension. Future genetic studies are needed in the CKD population to identify genetic variants that are associated with these pathological findings, particularly in African Americans. More prospective large population studies with non-malignant hypertension taking into account baseline creatinine, proteinuria, genetic predisposition, and effect of antihypertensive treatment would be ideal to demonstrate the phenomenon of either association or causality between benign hypertension and CKD.
Nephrosclerosis is a pathologic finding that requires investigation of potential causes rather than been spontaneously linked to non-malignant hypertension. We desire to advocate for precision medicine and banning labeling our nondiabetic CKD patients with benign hypertension as hypertensive nephrosclerosis.
